Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-549 | CAL-101 | 2 | 72 | 0.0032 | 4767.3 | 4911.3 | 1249.6 | -2.49 | 0.970 | 0.971 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 0.01 | 4791.5 | 4911.3 | 1249.6 | -2.0 | 0.975 | 0.976 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 0.032 | 4864.3 | 4911.3 | 1249.6 | -1.49 | 0.990 | 0.990 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 0.1 | 4768.5 | 4911.3 | 1249.6 | -1.0 | 0.970 | 0.971 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 0.32 | 4658.5 | 4911.3 | 1249.6 | -0.495 | 0.947 | 0.949 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 1.0 | 4324.0 | 4911.3 | 1249.6 | 0.0 | 0.875 | 0.880 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | CAL-101 | 2 | 72 | 3.2 | 3956.0 | 4911.3 | 1249.6 | 0.505 | 0.792 | 0.805 | 1.975 | BT549 CAL101 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.001 | 3200.5 | 4694.0 | 1249.6 | -3.0 | 0.637 | 0.682 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.0032 | 2956.8 | 4694.0 | 1249.6 | -2.49 | 0.570 | 0.630 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.01 | 3125.3 | 4694.0 | 1249.6 | -2.0 | 0.616 | 0.666 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.032 | 3052.5 | 4694.0 | 1249.6 | -1.49 | 0.596 | 0.650 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.1 | 3059.8 | 4694.0 | 1249.6 | -1.0 | 0.598 | 0.652 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 0.32 | 3022.3 | 4694.0 | 1249.6 | -0.495 | 0.588 | 0.644 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 1.0 | 2999.0 | 4694.0 | 1249.6 | 0.0 | 0.582 | 0.639 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Everolimus | 2 | 72 | 3.2 | 2940.8 | 4694.0 | 1249.6 | 0.505 | 0.566 | 0.627 | 1.909 | BT549 Everolimus 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.001 | 4217.3 | 4863.0 | 1249.6 | -3.0 | 0.860 | 0.867 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.0032 | 4850.8 | 4863.0 | 1249.6 | -2.49 | 0.997 | 0.997 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.01 | 4692.3 | 4863.0 | 1249.6 | -2.0 | 0.964 | 0.965 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.032 | 4563.5 | 4863.0 | 1249.6 | -1.49 | 0.936 | 0.938 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.1 | 4425.0 | 4863.0 | 1249.6 | -1.0 | 0.906 | 0.910 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 0.32 | 3970.0 | 4863.0 | 1249.6 | -0.495 | 0.803 | 0.816 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 1.0 | 3214.3 | 4863.0 | 1249.6 | 0.0 | 0.619 | 0.661 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | Pictilisib | 2 | 72 | 3.2 | 2299.8 | 4863.0 | 1249.6 | 0.505 | 0.365 | 0.473 | 1.960 | BT549 GDC0941 0 2 72 |
BT-549 | GDC-0980 | 2 | 72 | 0.001 | 4859.5 | 4792.0 | 1249.6 | -3.0 | 1.010 | 1.010 | 1.939 | BT549 GDC0980 0 2 72 |
BT-549 | GDC-0980 | 2 | 72 | 0.0032 | 4745.3 | 4792.0 | 1249.6 | -2.49 | 0.990 | 0.990 | 1.939 | BT549 GDC0980 0 2 72 |